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Abstract
Background: It is known that a paracrine mechanism exists between mesenchymal stem cells and target cells. This
process may involve microvesicles (MVs) as an integral component of cell-to-cell communication.
Methods: In this context, this study aims to understand the efficacy of MVs in in-vitro endometrial stressed cells in view
of potential healing in in-vivo studies. For this purpose, the presence and type of MVs secreted by amniotic mesenchymal
stem cells (AMCs) were investigated and the response of endometrial cells to MVs was studied using a dose-response
curve at different concentrations and times. Moreover, the ability of MVs to counteract the in vitro stress in endometrial
cells induced by lipopolysaccharide was studied by measuring the rate of apoptosis and cell proliferation, the expression
of some pro-inflammatory genes such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin 1β (IL-1β), and
metalloproteinases (MMP) 1 and 13, and the release of some pro- or anti-inflammatory cytokines.
Results: MVs secreted by the AMCs ranged in size from 100 to 200 nm. The incorporation of MVs was gradual over time
and peaked at 72 h. MVs reduced the apoptosis rate, increased cell proliferation values, downregulated pro-inflammatory
gene expression, and decreased the secretion of pro-inflammatory cytokines.
Conclusion: Our data suggest that some microRNAs could contribute to counteracting in-vivo inflammation of
endometrial tissue.
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Background
The regular uterine environment promotes normal em-
bryo development, but clinical or subclinical disorders
could contribute to pregnancy failure. As reviewed by
Hurtgen [1], endometritis is an important cause of re-
duced fertility in mares in which artificial insemination
by fresh or frozen semen may induce acute endometrial
inflammatory reactions. If these conditions are not
promptly resolved, infections become chronic and, in
old pregnant mares, often result in higher pregnancy
loss. A similar clinical endometritis also occurs in dairy
cows following parturition [2, 3]. Furthermore, cyto-
logical endometritis emerged as a problem of remarkable
importance for dairy cattle reproduction because ani-
mals suffering from this disorder present a persistent
inflammatory uterine environment even in the absence
of clinical symptoms. A reduced conception rate and
increased calving-to-conception intervals are conse-
quences of these uterine diseases [4–7].
Successful implantation requires a complex sequence
of signaling events that are crucial to the establishment
of pregnancy, and a large number of molecular media-
tors, influenced by the level of ovarian hormones, have
been involved in this early embryo-maternal interaction.
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These mediators include adhesion molecules, cytokines,
growth factors, lipids, and others [8, 9]. Koot et al. [10]
underlined that infertility could occur after the early phases
of implantation as a malfunction of the endometrium-
embryo ‘dialogue’. The degree of endometrial production
of these mediators could be impaired by persistent endo-
metritis. Indeed, pro-inflammatory factors transcripted in
bovine endometrial epithelial cells are elevated in cases of
subclinical or clinical endometritis [11]. Repeat-breeding
cows (animals that after three or more inseminations do
not get pregnant because of fertilization failure or early
embryonic death) show abnormalities in the growth factor-
cytokine network, specifically in endometrial epidermal
growth factor (EGF) concentration [12]. The EGF family
acts on the trophectoderm, promoting cell attachment and
embryo development [13], and its impairment could
explain the pregnancy failure in these animals.
Many therapies have been proposed to treat or prevent
mare endometritis. Post-mating endometritis is usually
treated with uterine irrigation and ecbolic, while the
acute endometritis treatment is performed with systemic
or intra-uterine antibiotics. However, these therapies are
not always effective for resolving chronic uterine inflam-
mation. The prevention, mainly in cattle, includes nutri-
tional supplements and hygienic conditions during
parturition. Commonly, therapies in use include hormo-
nal treatments with GnRH, exogenous gonadotrophins,
and prostaglandins [14], or the exploitation of assisted
reproductive techniques, such as in vitro embryo pro-
duction and embryo transfer. However, in case of infer-
tility due to endometrial damage, the embryo-maternal
interaction and the restoration of uterine receptivity
could be improved by regenerative medicine treatment.
Regenerative medicine has several applications in the
treatment of many pathologies in both human and veter-
inary medicine. Treatments are based on mesenchymal
stem cell (MSC) transplantation but, although engraft-
ment of the transplanted MSCs has been documented in
some cases [15–17], only a small percentage of the
injected MSCs engraft successfully in various disease
models [18–21]. In an irradiated murine model, endo-
metrial regeneration by bone marrow-derived MSCs has
been studied showing a low number of cells engrafted in
the regenerating endometrium [22]. Consistent with
these findings, some studies recently showed that the
regenerative ability of MSCs could be attributed to the
production of molecules and mediators capable of acti-
vating the intrinsic repair processes in the damaged
tissues. To date, the conditioned medium (CM) obtained
from in vitro cultured MSCs has been proven to be
sufficient to stimulate the structural and functional re-
generation of cardiac [20, 23], renal [19, 24], spinal cord
[25], and tendon [26] tissues. These results indicate that
the beneficial effects of MSCs can be attributed to the
activation of paracrine mechanisms enabling stimula-
tion of endogenous stem cells. These cells are respon-
sible for the bioactive soluble factors (lipids, growth
factors, and cytokines) known to inhibit apoptosis and
fibrosis, enhance angiogenesis, stimulate mitosis and/or
differentiation of tissue-resident progenitor cells, and
modulate the immune response [27]. In addition to sol-
uble factors, recent findings indicate that extracellular
vesicles are released from MSCs inside the CM and that
these can be involved as important mediators in cell-
to-cell communication [28]. Microvesicles (MVs) have
been categorized into exosomes (EXs), released from
the endosomal compartment, and shedding vesicles
(SVs), which bud directly from the cell membrane. MVs
contain various active molecules such as lipids, pro-
teins, mRNA, and microRNA (miRNA) [29]. It has
been demonstrated that CM and MVs can be used in
vitro and in vivo to repair tissue damage, increasing the
healing rate [26, 29, 30]. MVs are involved in a dynamic
mutual paracrine communication between the embry-
onic and the maternal environment at the early stage of
pre-implantation embryo development [31]. Equine
embryos at day 8 are thought to secrete MVs that can
modulate the functions of the oviduct epithelium
through transfer of early pregnancy factor (HSP10) and
miRNAs [32]. On the other hand, MVs can be secreted
from the maternal side, and endometrium-derived MV
miRNAs are revealed to have potential targets in bio-
logical pathways highly relevant for embryo implant-
ation [33]. Uterine miRNAs are suggested to play a
potential regulatory role in the development and pro-
gression of bovine subclinical endometritis. Indeed,
Hailemariam et al. [34] demonstrated that there is an
aberrant expression of 23 miRNAs in cows with
subclinical endometritis compared with healthy cows.
Furthermore, they observed a similar expression of
miRNA patterns in cytobrush samples from sick cows
and in vitro cultured endometrial cells challenged by
lipopolysaccharide (LPS). This suggests that in vitro
endometrial cell culture, treated with LPS, could
be an excellent model to test potential regenerative
medicine treatments for endometritis. In human medicine,
the different pattern of miRNAs between women
with and without endometriotic disease have been
proposed as biomarkers that could underpin the de-
velopment of a noninvasive diagnostic test for endo-
metriosis [35].
In this context, the aims of this study were to identify
the presence and type of MVs secreted by amniotic mes-
enchymal progenitor cells (AMCs), and to elucidate
whether equine endometrial cells could be targeted by
MVs in vitro. In addition, we considered whether MVs
are able to counteract an in vitro endometrial cell in-
flammatory process induced by LPS.
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Methods
Materials
Uteri samples were collected from horses slaughtered in
a national slaughterhouse under legal regulation. Chemi-
cals were obtained from Sigma-Aldrich Chemical (Milan,
Italy) unless otherwise specified, and tissue culture plas-
tic dishes were purchased from Euroclone (Milan, Italy).
Study design
Initially, amniotic cells were isolated and cultured to
produce MVs that were characterized using a Nanosight
instrument (Nanoparticle tracking analysis, NTA; Nano-
Sight Ltd., Amesbuty, UK). Endometrial cells were iso-
lated, and specific endometrial genes were identified by
qualitative reverse transcription polymerase chain reac-
tion (RT-PCR). Isolated endometrial cells were used as
the target for different concentrations of MVs. Further-
more, the effect of MVs on endometrial cells treated by
LPS was analyzed by quantitative RT-PCR (qRT-PCR)
expression of inflammatory genes, evaluation of the re-
lease of different cytokines, and viability cell tests. Fi-
nally, the presence of some miRNAs, regulating
inflammation, inside the MVs was evaluated.
Tissue collection
Allanto-amniotic membranes were obtained at term
from normal pregnancies in three mares. Samples of
allanto-amnion were transported at 4 °C in calcium- and
magnesium-free phosphate-buffered saline (PBS; Euro-
clone, Milan, Italy) supplemented with 4 mg/mL ampho-
tericin (Euroclone), 100 UI/mL penicillin and 100 mg/
mL streptomycin (Euroclone), and were processed
within 12 h of collection. The amniotic membrane was
mechanically separated from the allantois and the isola-
tion of AMCs was performed as previously reported by
Lange-Consiglio et al. [36].
Endometrial samples were obtained during the repro-
ductive season from normal-cycling mares at diestrus
stage (early-mid luteal phase). Before slaughtering, 5 ml
of blood was collected in heparinized tubes from all
mares. After centrifugation, plasma was separated, kept
refrigerated, and immediately transported to the labora-
tory for progesterone determination by a quantitative
enzyme linked fluorescent assay (ELFA) based on the
MiniVidas (Biomerieux, Firenze, Italy) technology. Ac-
cording to the manufacturer, the measurement range of
the assay varied from 0.25 to 80 ng/ml with an intra-
assay variation of 4.12 % and an inter-assay variability of
6.32 %.
Only uteri belonging to mares with an obvious corpus
luteum on the ovary and progesterone levels between 6
and 20 ng/ml, indicative of the early/mid diestral phase
of the estrous cycle [37], were used for endometrial frag-
ment collection and ensuing cell culture.
Tissue fragments for RNA isolation were immediately
immersed in RNA Later solution, whereas those des-
tined for cell isolation and the expansion procedure were
kept at 4 °C in saline solution supplemented with 4 μg/
ml amphotericin B, 100 IU/ml penicillin, and 100 μg/ml
streptomycin and processed within 8 h.
Cell isolation
Amniotic membrane-derived mesenchymal cells were
isolated as recently reported by Lange-Consiglio et al.
[36]. Briefly, amnion fragments were incubated for
9 min at 38.5 °C in PBS containing 2.4 U/mL dispase
(Becton Dickinson, Milan, Italy). After a resting period
(5–10 min) at room temperature in high-glucose Dul-
becco’s modified Eagle’s medium (HG-DMEM; Euro-
Clone, Milan, Italy), supplemented with 10 % heat-
inactivated fetal bovine serum (FBS) and 2 mM L-glu-
tamine, the fragments were digested with 0.93 mg/mL
collagenase type I and 20 mg/mL DNAse (Roche, Mann-
heim, Germany) for approximately 3 h at 37 °C. The am-
nion fragments were then removed, and mobilized cells
were passed through a 100-μm cell strainer before being
collected by centrifugation at 200 × g for 10 min.
Endometrial cells from diestrum uteri of mares were
obtained according to the protocol described by Dono-
frio et al. [38] and slightly modified for equine cells.
Briefly, the endometrium was digested in sterile filtered
Hank's buffered salt solution supplemented with 2 mg/
ml collagenase II, 4 mg/ml bovine serum albumin, and
0.4 mg/ml DNase I for 90 min at 38.5 °C in a shaking
bath. Cells were then filtered through a membrane with
a pore size of 80 μm and centrifuged at 200 × g for
10 min, then washed twice in PBS. This protocol allowed
for the isolation of the endometrial stromal portion. Be-
fore seeding, cells were counted using a Burker chamber
with the Trypan Blue dye exclusion assay.
Cell expansion
Endometrial cell (EDC) cultures were established in HG-
DMEM supplemented with 10 % FBS, penicillin (100
UI/ml), streptomycin (100 μg/ml), 0.25 μg/ml amphoter-
icin B, and 2 mM L-glutamine. Medium was supple-
mented with 10 ng/ml EGF for AMC cultures.
To remove non-adherent cells for both cell lines the
medium was replaced for the first time after 72 h, and
then changed either twice per week thereafter or accord-
ing to the experiment requirements. For maintenance of
cultures, cells were plated in flasks of 25 cm2 at a density
of 1 × 105 cells/cm2 and incubated at 38.5 °C in a hu-
midified atmosphere with 5 % CO2. Adherent cells were
detached with 0.05 % trypsin-EDTA just prior to reach-
ing confluence (80 %) and then reseeded for culture
maintenance at a density of 1 × 104 cells/cm2.
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A detailed characterization of these cells was per-
formed in the paper of Corradetti et al. [39]. In this
study, a molecular characterization of EDCs was per-
formed only at passage (P)0 as a de facto control for
gene expression.
Isolation and measurements of MVs
MVs were obtained from the culture media of AMCs de-
rived from three different placentas, cultured for 1 week
with HG-DMEM supplemented with 10 % MV-deprived
FCS and overnight in HG-DMEM deprived of FCS and
supplemented with 0.5 % BSA (Sigma). The overnight
culture media were pooled and centrifuged at 2000 × g
for 20 min to remove debris, then at 100,000 × g (Beck-
man Coulter Optima L-100 K ultracentrifuge) for 1 h at
4 °C, washed in serum-free medium 199 containing N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES;
25 mM) and submitted to a second ultracentrifugation
under the same conditions. After ultracentrifugation, the
pellet was immediately resuspended in HG-DMEM, and
a fraction of the resuspended pellet was taken for mea-
surements of MV size and concentration. A second frac-
tion was labeled with fluorochrome PKH-26 and the
remaining part of the pellet was cryopreserved with 1 %
dimethylsulfoxide at –80 °C and used for the in vitro
test. The size and concentration of MVs were evaluated
by the Nanosight LM10 instrument, which permits dis-
crimination of microparticles less than 1 μm in diam-
eter. The software (NTA 2.0 analytic software) allows
the analysis of video images of particle movement
under Brownian motion and the calculation of diffusion
coefficient, sphere equivalent, and hydrodynamic radius
of particles by using the Strokes–Einstein equation.
This instrument was configured with a 405-nm laser
and a high-sensitivity sCMOS camera (OrcaFlash2.8,
Hamamatsu C11440, NanoSight Ltd). Videos were
collected and analyzed using the NTA software with
the minimal expected particle size, minimum track
length, and blur setting all set to automatic. Ambient
temperature was recorded manually and did not exceed
25 °C. Each sample (5 μl) was diluted in sterile physio-
logical solution to a final volume of 1 ml. Samples were
analyzed within 15 min of the initial dilution with a
delay of 10 s between sample introduction and the start
of the measurement. For each sample, multiple videos
of 30 s duration were recorded generating replicate his-
tograms that were averaged.
MVs labeling with PKH-26
To trace in vitro MVs by fluorescence microscopy, MVs
from AMCs were labeled with the red fluorescence ali-
phatic chromophore intercalating into lipid bilayers
PKH26 dye (Sigma). Briefly, after ultra-centrifugation,
the MV pellet was diluted to 1 ml with PKH-26 kit and
2 μl of fluorochrome was added to this suspension and
incubated for 30 min at 38.5 °C. At the end of the reac-
tion, 7 ml of serum-free DMEM was added to the sus-
pension that was ultra-centrifuged again at 100,000 g for
1 h at 4 °C. The final pellet was immediately resus-
pended in HG-DMEM.
Incorporation of MVs in endometrial cells
To study the incorporation capacity of MVs into endo-
metrial cells, a dose-response growth was performed in
three replicates. Endometrial cells were seeded at a
density of 60 × 103 on culture slides (13 mm; Nalgen
Nunc International, Rochester, NY, USA) in 24 wells
and co-cultured with 10, 20, 30, 40, and 50 × 106 MVs/
ml labeled with PKH-26 dye, and pre-incubated or not
with trypsin (0.5 mM) for 24, 48, and 72 h at 38.5 °C.
At the end of each experimental condition, cells were
nuclear stained with 10 μg/ml Hoechst 33343 for
15 min at 38 °C. The uptake of MVs was evaluated by
an Olympus BX51 microscope equipped with a Scion
Corporation 1394 video camera interfaced with a
computer provided with software for image acquisition
and analysis (Image-Pro Plus 5.1-Media Cybernetics,
Immagini & Computer, Bareggio, Italy). Excitation
wavelength was positioned at 550 nm while emission
wavelength was set at 567 nm. Hoechst 33342 dye
(Sigma) was excited at 353–365 nm while the emission
wavelength was set at 460 nm. To detect the intensity
of fluorescence, a semi-quantitative analysis was per-
formed. Different images were acquired for each condi-
tion and then, for each image, the area of interest (AOI;
where the signal was present) was manually defined by
the user. Inside the AOI, up to three different back-
ground signals were sampled. The background areas
were positioned by the user only where the fluorescent
signal was not specific. The maximum value collected
from the background areas was then used to define the
threshold. Only fluorescence with an intensity above
the threshold was considered to indicate fluorescence
due to labeled MVs. Finally, the program measured the
signal intensity expressed in arbitrary units (a.u.).
Confocal microscopy analysis to assess internalization
of MVs was performed using a Leica SP2 laser scanning
confocal microscope (Leica Microsystems Srl, Italy)
equipped with a PL Fluotar 20× AN 0.5 Dry objective.
In vitro effect of MVs on endometrial cells treated with LPS
The dose-response curve of LPS on endometrial cells
was studied showing that 10 ng/ml and 12–24 h were
the dose and the times most effective in inducing cellu-
lar stress evaluated by an apoptotic study (data not
shown). Sixty thousand cells were incubated at the
same time with LPS 10 ng/ml and 40 × 106 MVs/ml for
3, 12, and 24 h. In another experimental condition,
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endometrial cells were treated first for 3 h with LPS
and then with MVs at the same concentrations and
times. In the last experiment, endometrial cells were
treated first for 24 h with MVs and then with LPS
10 ng/ml. Endometrial cells alone or endometrial cells
with LPS or MVs only were used as controls at different
times. At the end of each experimental condition, the
MTT reduction assay method and apoptotic test were
used to analyze cell proliferation and viability of cells
on some samples. Cells from other samples were de-
tached with 0.05 % trypsin-EDTA, centrifuged, and
cryopreserved for molecular biology studies in liquid
nitrogen using standard cryopreservation protocols.
The supernatants were destined for the evaluation of
cytokines released from endometrial cells. All experi-
ments were performed in three replicates.
Viability cell tests
Cell proliferation test by MTT reduction assay method
The MTT reduction assay method (Chemicon, Temecula,
CA, USA) estimates the activity of the enzyme
dehydrogenase by converting the MTTcompound (3-(4,5-
dimethylthiazol- 2-yl)-2,5-diphenyletrazolium bromide)
into formazan by the mitochondria. The measurement
was performed with a spectrophotometer (Perking
Elmer HTS 700 plus; Boston, MA, USA) at the absorb-
ance reading of 570 nm for each sample. Briefly, at each
experimental condition of in vitro effect of MVs on
endometrial cells treated with LPS, cells were washed
twice in PBS, and 1 ml of 5 mg/l MTT solution was
added to each well. Avoiding light, plates were then
placed in a humidified incubator at 37 °C for 4 h. The
supernatant was discarded, 1 ml of dimethylsulfoxide
was added as an extracting solution, and plates were in-
cubated for 2 h until the precipitations were resolved
completely for spectrophotometric reading. This test
was performed in three replicates.
Apoptotic test
The percentage of apoptotic cells was assessed using an
Annexin-V-FITC Apoptosis Detection KIT (Sigma) fol-
lowing the manufacturers’ instructions; 500 μl of cells
(5 × 105 cells) were incubated with 5 μl of Annexin V so-
lution and with 10 μl propidium iodide for 1 h at room
temperature while protected from light. Apoptosis rates
were evaluated by conventional fluorescence analysis
using a BX 51 microscope (Olympus) equipped with a
DMU filter set. One hundred cells were analyzed using
a combination of 488/560 nm emission. Cells at the
early stage of apoptosis stained with the annexin V-
FITC alone. Live cells showed no staining with either
propidium iodide or Annexin V-FITC. Cells dead for
apoptosis were stained by both propidium iodide and
Annexin V-FITC, and cells dead for necrosis were
stained by propidium iodide alone. The apoptotic test
was performed in three replicates.
Molecular biology studies
Characterization of endometrial cells
After isolation from endometrial tissue, cells were ana-
lyzed to detect the expression of specific endometrial
genes as previously reported [39]. Total RNA was ex-
tracted from endometrial cells immediately after isola-
tion (P0) using TRI Reagent Solution (Life Technologies,
Monza, Italy) and conventional RT-PCR was performed
with RBC Taq DNA Polymerase (RBC Bioscience) using
previously optimized primers [39]. The primer se-
quences and conditions are shown in Tables 1 and 2.
Glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH)
was employed as a reference gene.
Gene expression of pro-inflammatory cytokines
Genes involved in the inflammatory process, such as
interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor
necrosis factor α (TNF-α), were analyzed by qRT-PCR
under all experimental conditions. The mRNA expres-
sion levels of all genes were measured in three samples
(biological replicates). Total RNA was isolated using the
mirVana™ miRNA isolation Kit (Life Technologies) ac-
cording to the manufacturer’s protocol and stored at
−20 °C. The concentration and purity of RNAs were
evaluated three times by the NanoQuant spectropho-
tometer (Thermo Scientific, USA) and, in order to verify
the integrity of extracted RNA, eight samples that were
randomly chosen were analyzed on a Bioanalyzer 2100
using the Agilent RNA 6000 Pico Kit (Agilent). Accord-
ing to the RNA quantity, each sample was normalized to
the final RNA concentration of 10 ng/μl.
RT-PCRs were performed with the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems/
Life Technologies, Carlsbad, CA, USA) using 100 ng of
RNA per reaction.
All the qPCR experiments were run in triplicates (tech-
nical replicates) using the qPCR protocol described by
TaqMan Fast Gene Expression Assays (Life Technologies™)
on a 7500 Fast Real-time PCR System instrument (Applied
Biosystems by Life Technologies™). To assess gene expres-
sion, each target gene and the GAPDH, as the housekeep-
ing control gene, were co-amplified. The assay primers
were available and synthesized by Life Technologies™.
Average target gene threshold cycle (ΔCtg) for each
sample (calculated using the CT values of the technical
replicates within each experimental conditions) were
normalized to the average GAPDH values (ΔCtGAPDH)
of the same cDNA sample. Then the expression varia-
tions calculated were normalized to the internal control
(i.e., control cell at 3 h) using the ΔΔCt method.
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Finally, the fold-change expression of each gene was
calculated as 2−ΔΔCT [40].
Gene expression of metalloproteinases
Matrix metalloproteinase 1 (MMP-1) and matrix metal-
loproteinase 13 (MMP-13) were selected to evaluate the
effect of MVs to contrast LPS activity. Gene expression
was performed with the SYBR green method in a MyiQ
iCycler thermal cycler (Biorad). Triplicate PCR reac-
tions were carried out for each sample, analyzed using
primer sequences reported in Table 1. The reactions
were set on a strip in a final volume of 25 μl by mixing,
for each sample, 1 μl of cDNA, 12.5 μl of 2× concen-
trated SYBR Premix Ex Taq II (Takara Bio) containing
SYBR Green as a fluorescent intercalating agent,
0.2 μM forward primer, 0.2 μM of reverse primer, and
MQ water. PCR efficiencies were tested and found to
be close to 1. The thermal profile for all reactions was
30 s at 95 °C and then 40 cycles of 5 s at 95 °C, and
30 s at 60 °C. Fluorescence monitoring occurred at the
end of each cycle. The efficiency of amplification for
each primer was monitored through the analysis of ser-
ial dilution. Additional dissociation curve analysis was
performed, and in all cases showed a single peak. The
data thus obtained were analyzed using the iQ5 optical
system software version 2.0 (BioRad). The expression of
each gene was normalized to the reference gene
GAPDH in order to standardize the results by eliminat-
ing variation in cDNA quantity. Sequences used are
listed in Table 1.
miRNA analyses by RNA extraction and PCR amplification
The MV pellet was subjected to RNase digestion to re-
move extraneous ribonucleic acids [41]. Total RNA was
isolated from a pool of different MVs and amniotic-
derived cell preparations using the NucleoSpin® mRNA
kit (Macherey-Nagel, Germany), in combination with
TRIzol® lysis and purification of small and large RNA in
one fraction (total RNA). RNAs were quantified using a
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). RNA quality was
checked using the Agilent Bioanalyser 2100 (Agilent,
Santa Clara, CA, USA), where the presence of small
RNAs was verified in both MV and cell samples.
RNAs from all samples were reverse transcribed with
the miScript Reverse Transcription Kit and the cDNA
was then pre-amplified using the miScript PreAMP
PCR Kit (all from Qiagen, Valencia, CA, USA), follow-
ing the manufacturer’s instruction with some modifica-
tion: miScript PreAMP Primer Mix was replaced with
miR-specific primers: hsa-miR-26a-2, -335, -146a, and
SNORD95 as forward primer, and miScript Universal
Primer as reverse primer in separate reactions. Homo
sapiens hsa miRNA were perfectly homologous with
Equus caballus eca miRNA sequence. PCR was per-
formed on pre-amplified products using the PCR Mas-
ter Mix (2×) (Thermo Fisher Scientific Inc., Waltham,
MA, USA), with the same primer couple: hsa-miR-26a-
2, -335, -146a, SNORD95 in combination with miScript
Universal Primer. The small nucleolar snoRNA, C/D
Box 95 SNORD95 was used as the positive control.
Table 1 Oligonucleotide sequences used for reverse transcription polymerase chain reaction analysis
Reference
sequence
Markers Forward Reverse Annealing
temperature
bp
XM_001498494.3 Progesteron Receptor (PR) GTCAGTGGACAGATGCTGTA CGCCTTGATGAGCTCTCTAA 55 °C 255
NM_001256979.1 Membrane-associated progesterone
receptor (MPR)
GCCAAGTATCGTTACCGGAG AAGAGGATCTGGAGCGTGTG 55 °C 173
XM_001914705.2 Progester one receptor membrane
component 1 (PGRMC1)
TCAACGGCAAGGTGTTCGAC GGCTCTTCCTCATCTGAGTA 58 °C 280
XM_003364827.1 Homeobox protein Hox-A9-like
(Hoxa9)
ACGCTGGAACTGGAGAAAGA CTTTCGCTCGGTCCTTATTG 55 °C 160
NM_001163856.1 Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH)
AGATCAAGAAGGTGGTGAAG TTGTCATACCAGGAAATGAGC 59 °C 178
NM_001081847.2 Matrix metallopeptidase 1 (MMP-1) ACTGCCAAATGGACTTCAAGCTGC TCTTCACAGTGCTAGGAAAGCCG 60 °C 158
NM_001081804.1 Matrix metallopeptidase 13
(MMP-13)
CTCTGGTCTGCTGGCTCACGC CCAAACTCGTGTGCAGCGAC 60 °C 132
Table 2 Oligonucleotide sequences synthesized by Life Technologies
Assay ID Gene
symbol
Entrez gene
ID
NCBI
assembly
CHR Location on NCBI genome
assembly
Location on transcript or
gene
Ec03467871_m1 TNF 100033834 2.1 20 31359792 318
Ec03468680_m1 IL-6 100034196 2.1 4 54424314 468
Ec04260298_s1 IL-1B 100034237 2.1 Un|NW_001871813.1 5795 254
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Negative controls using water in place of the pre-Amp
product were performed alongside each reaction. The
cycling conditions were 3 min at 95 °C, followed by
35 cycles of 30 s at 95 °C, 30 s at 58 °C, 1 min at 72 °C,
and finally 7 min at 72 °C. The amplified PCR products
were separated electrophoretically on 2.5 % agarose
gels, and visualized under UV, using the GeneRuler
50 bp as a DNA ladder (Thermo Fisher Scientific Inc.).
Cytokines
Cytokine release (IL-6, transforming growth factor
(TGF)-β, and TNF-α) was measured in cell-free super-
natants obtained by centrifugation at 1200 rpm for
5 min and stored at −80 °C until measurement. Cyto-
kine production was assessed by commercially available
sandwich ELISAs (Bioptis SA, Liege, Belgium). ELISAs
were performed according to the supplier’s instructions.
Results are expressed in pg/ml. The limit of detection
was 15.6 pg/ml for all cytokines tested.
Statistical analysis
For quantitative PCR experiments, data were analyzed
by one-way analysis of variance (ANOVA). Also, cell via-
bility data were analyzed by one-way ANOVA applying a
Bonferroni correction.
For cytokines, statistical differences were determined
using ANOVA followed by Dunnett’s multiple compari-
son test, the Tukey–Kramer multiple comparisons test
or unpaired t test.
Differences were considered statistically significant if
the value of P was <0.05.
Results
Tissue collection and cell isolation
Cells were selected for their ability to adhere to plas-
tic. For AMCs, the initial viability was >90 %, whereas
for EDCs it was >85 %. EDCs (Fig. 1a) and AMCs
(Fig. 1b) displayed fibroblast-like morphology. Mo-
lecular biology analyses at P3 showed that AMCs
showed a typical mesenchymal stromal phenotype,
with the expression of markers such as CD29, CD44,
CD106, CD105, and MHCI, but not CD34 and MHCII.
Moreover, AMCs showed differentiative potential in
mesenchymal (osteogenic, adipogenic, and chondro-
genic) and ectodermic lines (neurogenic) as reported
by Lange-Consiglio et al. [36].
The molecular biology study on endometrial cells at
P0 confirmed that these cells were endometrial cells
because of the expression of PR, MPR, PGRMC1,
HOXA-9 (Fig. 1c).
Isolation and measurement of MVs
In all the studied samples, the viability of AMCs at the
time of MV collection was 99 % as detected by trypan
blue exclusion. By Nanosight, the size of MVs ranged
from 50 to 670 nm, with a mean size of 258 ± 55 nm for
three samples. The number of MVs ranged from 800 to
4700 particles/cell, with a mean value of 2550 ± 71 parti-
cles/cell (corresponding to 540 × 106 particles/ml of
medium). In a previous study [42], transmission electron
microscopy (TEM) analysis revealed the presence of
variably sized extracellular membranous vesicles bud-
ding from, or lying near, the cell of origin. The size of
MVs ranged from 100 nm to 1000 nm, with a predomin-
ance of vesicles between 100 and 200 nm. Because of
the size, by Nanosight and TEM, and morphological
characteristics, the vesicles observed were mainly con-
sidered as shedding vesicles.
Incorporation of MVs in endometrial cells
As seen by fluorescence microscopy, in all the studied
samples no fluorescence signal was detectable up to the
sixth hour of co-incubation of MVs with endometrial
cells, and only nuclei stained with Hoechst 33342 were
visible (Fig. 2a). The increase in uptake of 40 × 106 MVs/
ml by endometrial cells between 24 h and 72 h is
showed in Fig. 2b, c, d and e. No signal was detected
after treatment of MVs with trypsin. The incorporation
of MVs is gradual and constant at 24 h with a concentra-
tion of 40 × 106 MVs/ml, and suddenly increases at a
concentration of 50 × 106 MVs/ml. The uptake of MVs
drastically increased at 48 h at a concentration of 40 ×
106 MVs/ml and decreased at a concentration of 50 ×
106 MVs/ml. The internalization and accumulation of
MVs peaked at 72 h for all the different concentrations
but, once again, decreased at a concentration of 50 × 106
MVs/ml (Fig. 3a).
As seen by confocal microscopy, after 24 h of incuba-
tion with MVs, endometrial cells showed a fine granular
fluorescent pattern within their cytoplasm, indicating in-
corporation of MVs (Fig. 3b and c).
In vitro effect of MVs on endometrial cells treated with LPS
Viability cell tests The effect of LPS and MVs was eval-
uated by apoptotic and cell proliferation tests. The
rate of cells at the early stage of apoptosis increased
dramatically on treatment with LPS; indeed, the per-
centage of apoptotic cells reached 55 ± 4.1 % at 12 h of
stress, decreasing to 40.48 ± 4.82 % at 24 h. The rate
of apoptosis due to MVs is not statistically different
from endometrial cells alone (Fig. 4a). The results of
the cell proliferation test showed the opposite trend to
the apoptotic test, confirming the effect of LPS and
MVs (Fig. 4b).
MVs were able to counteract the action of LPS either
when used simultaneously with LPS or when incorpo-
rated from endometrial cells 24 h before the treatment
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with LPS. In this condition, cells previously treated with
MVs and after being exposed to LPS had a lower apop-
totic rate (P < 0.05) than the control cells, at both 12 and
24 h of experiment (12.01 ± 1.38 % vs 18.05 ± 1.34 % at
12 h and 15.56 ± 1.5 % vs 24.5 ± 2.78 % at 24 h). On the
other hand, the stress induced by LPS exposure before
the treatment with MVs was not contrasted by MVs and
the apoptotic rate increased up to 63.16 ± 6.8 % at 24 h
(Fig. 4c). The results of the cell proliferation test showed
the opposite trend to the apoptotic test (Fig. 4d).
Fig. 1 Morphology of a endometrial (EDCs) and b amniotic cells. c Expression of specific endometrial markers revealed by qualitative PCR on
endometrial cells at passage 0 (P0). GAPDH glyceraldehyde-3-phosphate dehydrogenase, HOXA9 homeobox protein Hox-A9-like, MPR membrane-
associated progesterone receptor, NC negative control, PGRMC1 progesterone receptor membrane component 1, PR progesterone receptor
Fig. 2 Representative micrographs of internalization by endometrial cells of MVs labeled with PKH-26. Under a fluorescent microscope, the
endometrial cell nuclei are blue and the MVs are red. a No incorporation of MVs pre-incubated with trypsin. Incorporation of 40× 106 MVs/ml into the
target cells from b 24 h, c 36 h, d 48 h, and e 72 h, respectively
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Molecular biology study
The expression of some pro-inflammatory genes was
evaluated by qRT-PCR. Endometrial cells, LPS, and
MVS were tested alone. Data were obtained from three
samples and are shown in Fig. 5. LPS at 3 h significantly
upregulated (P < 0.05) the expression of TNF-α and IL-6
(0.0019 ± 0.317E–6 and 10.54 ± 0.014, respectively) and of
ILβ-1 at 24 h (9.91 ± 0.017). Endometrial cells used as
controls (CTR) and MVs did not induce expression of
pro-inflammatory genes. In the experiment with simul-
taneous use of LPS and MVs, the action of LPS was
counteracted by MVs; indeed, the expression of IL-6 at
first increased significantly (P < 0.05) at 3 h by LPS and
then fell significantly in the presence of MVs either at
12 h (2.41 ± 0.039) or at 24 h (1.15 ± 0.081). IL-1β at
24 h was completely and significantly (P < 0.05) down-
regulated (0.22 ± 0.0008). The expression of TNF-α is
not dependent on the presence of MVs.
When LPS was used for 3 h before adding the MVs, the
action of LPS was neutralized by the presence of MVs.
Indeed, the expression of IL-6 at 3 h, 12 h, and 24 h was
2.08 ± 0.0019, 1.75 ± 0.0033, and 2.65 ± 0.0013, respectively,
compared to the treatment with LPS only. In addition, the
expression of IL-1β was significantly (P < 0.05) downregu-
lated at 24 h (0.21 ± 0.0016).
Under the final condition of MVs for 24 h and then
LPS, the expression of all genes was downregulated.
TNF-α expression at 3 h fell 0.0002-fold compared to
the treatment with LPS. IL-6 expression was statistically
(P < 0.05) downregulated at each time point, and IL-1β
was statistically (P < 0.05) downregulated at 24 h.
A moderate but significant (P < 0.05) increase in the
expression was observed for MMP-1 (5.18 ± 0.44) and
MMP-13 (2.69 ± 0.19) compared to untreated cells
when endometrial cells were exposed to LPS for 24 h
(Fig. 5d and e). The presence of MVs, simultaneously
to LPS, significantly counteracted the effect of LPS on
the expression of metalloproteinases as shown by the
striking reduction in the expression levels for MMP-1
(1.67 ± 0.14) and MMP-13 (0.36 ± 0.11).
miRNA analyses by RNA extraction and PCR amplification
Expression of specific miRNA was determined by PCR
assay that showed the presence of miR-26a-2, miR-335,
and miR-146a in both MVs and cells isolated from the
amniotic membrane (Fig. 5f ).
Cytokines
The results of the release over time (3, 12, and 24 h) of
pro-inflammatory (TNF-α and IL-6) and anti-inflammatory
Fig. 3 MV uptake. a Graph of dose/exposure time for microvesicle (MV) incorporation. The uptake of MVs drastically increased at 72 h for
all concentration but decreased at 50 × 106/ml MVs. Data represent the mean and SD of three independent experiments. b, c Representative z-stack
orthogonal projection micrographs showing the internalization of MVs as detected by confocal microscopy in two group of endometrial cells
co-cultured with MVs for 24 h. The images were taken at different plans scanned every 0.5 μm from top to bottom of the nucleus and showed at
different magnification. a.u. arbitratry units
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(TGF-β) cytokines by endometrial cells stimulated with
10 ng/ml of LPS and treated with MVs are shown
graphically in Fig. 6.
Cells stressed with LPS secreted significantly (P < 0.05)
more TNF-α and IL-6 at 3 h and 12 h, respectively,
when compared to control cells and cells treated by
MVs. The MVs, used simultaneously or incorporated
from endometrial cells 24 h before the treatment with
LPS, were able to counteract the action of LPS and sig-
nificantly (P < 0.05) and equally decreased the produc-
tion of TNF-α and IL-6, mainly between 12 h and 24 h.
Cells incubated with LPS for 3 h before the treatment
with MVs secreted significantly more TNF-α and IL-6
when compared to all the other experimental conditions.
TGF-β was constitutively produced by control cells
but the treatment with MVs induced a higher release
(P < 0.05) of TGF-β, mainly when used simultaneously
with LPS or incorporated from endometrial cells 24 h
before the treatment with LPS. No efficacy of MVs was
evident after LPS-induced stress of cells for 3 h before
the addition of MVs.
Discussion
MVs are secreted by MSCs. Although bone marrow rep-
resents the most widely investigated source of MSCs,
cells harvested from bone marrow have limited potential
in terms of in vitro proliferation capability [43, 44] and
do not appear to noticeably improve long-term function-
ality [45] compared to those from extra-fetal tissues.
AMCs have already been demonstrated to be an excel-
lent source for the treatment of tendon diseases in horse
[26]. Furthermore, Lange-Consiglio et al. [46] used the con-
ditioned medium derived from AMCs for the treatment of
horse tendon diseases and showed that the positive evolu-
tion of spontaneous tendon injuries in competition
horses was comparable to that achieved with AMCs,
thereby showing that AMC-CM had angiogenic and
immunomodulatory properties mediated by paracrine
mechanisms. Corradetti et al. [39] demonstrated that
equine AMCs share the same transcriptional profile as
endometrial cells and express genes that are involved in
early pregnancy, pre-implantation, and conceptus de-
velopment. In addition, co-culture of endometrial cells
by transwell in the presence of AMCs, or incubated
with CM, showed a significant increase in the prolifera-
tion rate of endometrial cells compared to fibroblasts
and the CM secreted by them. All these preliminary
data suggest that AMCs and CM exert regenerative ef-
fects through paracrine mechanisms, and that AMCs
and their CM may have the potential to improve endo-
metrial cell replenishment. Since MVs are contained in
the CM, the aim of the present study was to investigate
the role of MVs produced by AMCs in in-vitro cell-to-
cell communication that could ultimately lead to endo-
metrium repair. We ultimately aim to demonstrate that
they could be used as effective tools for regenerative
medicine purposes, especially in the reproduction field.
Our results show that AMCs secrete MVs (with a mean
size of 258 nm) as detected by a Nanosight instrument,
and this size allows us to categorize them as shedding
vesicles. Moreover, we found that MVs are easily internal-
ized by endometrial cells. Fluorescent microscopy analysis
Fig. 4 Results of viability and proliferation. The rate of cells at a the early stage of apoptosis and b absorbance values of the cell proliferation test in
control cells. c Early apoptosis rate and d absorbance values of the cell proliferation test in treated cells. Data represent the mean and SD of three
independent experiments. Values labeled with different letters are statistically different within each time point (3 h, 12 h and 24 h) (P < 0.05). MV
microvesicle, LPS lipopolysaccharide
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suggests that the uptake of MVs by endometrial cells starts
at 6 h after co-culture and increases gradually at 24 h, ris-
ing to the maximum internalization at 72 h at all different
concentrations. At a concentration of 50 × 106 MVs/ml, a
decrease at 48 h and 72 h was detected. We hypothesize
that after 48 h and 72 h of exposure at 40 × 106/ml, the
cells are saturated and phagocytosis of MVs, for the re-
lease of their contents into the cell cytoplasm, begins. This
phagocytosis probably results in the destruction of the
MV membranes and, consequently, in the loss of fluores-
cence signal. Cocucci et al. [47] demonstrated that the in-
ternalization of MVs is the result of the direct fusion or
endocytic uptake by target cells. Once internalized, the
MVs fuse their membrane with that of endosomes, mak-
ing a horizontal transfer of their contents into the cyto-
plasm of the recipient cells. Alternatively, MVs can remain
segregated inside the endosomes and be phagocytized by
lysosomes or eliminated from the cells after fusion with
the plasma membrane through a mechanism of transcyto-
sis [47]. Our data show that horizontal transfer of the con-
tents of MVs within endometrial cells could be one of the
mechanisms of action of MVs, although other methods of
interaction may occur simultaneously. The process of up-
take and internalization of MVs by the endometrial cells
could also be facilitated by the presence of surface cell re-
ceptors. This hypothesis is confirmed by the results of
Fig. 5 Quantitative RT-PCR analysis for the expression of a TNF-α, b IL-6, and c IL-1β in endometrial cells in different experimental conditions.
Expression of d MMP-1 and e MMP-13 in endometrial cells exposed to 10 ng/ml LPS (LPS10 24h) and simultaneously to 10 ng/ml LPS and MVs
(LPS10 24h + MV). Expression levels have been normalized to the reference gene (GAPDH). Data are represented as fold-change compared with
the expression observed in endometrial cells (control, CTR). Values are mean ± SD (n = 3). P values of expression levels in respect to control are
shown above groups when significant in panels a–c, and the values labeled with different letters are statistically different (P < 0.05) in panels
d and e. f PCR assays to determine the presence of different miRNA (miR-26a-2, miR-335, miR146a), and small nucleolar snoRNA, C/D Box 95
(SNORD95; positive control) in MVs and cells (C) isolated from amniotic membrane. CTR control, IL interleukin, L molecular weight ladder, LPS
lipopolysaccharide, MMP matrix metalloproteinase, MV microvesicle, NC negative control, ns not significant, TNF tumor necrosis factor
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experiments in which MVs were treated with trypsin be-
fore being incubated with endometrial cells. Having identi-
fied that the endometrial cells represent target cells for
MVs secreted by equine AMCs, a further aim of this study
was to understand whether MVs might be involved in the
regeneration of endometrial diseases. Obviously, due to the
difficulty of studying the repair systems of endometritis in
vivo, we recapitulated in vitro the inflammatory process by
stimulating cells with LPS.
The inflammatory response is a complex process in-
volving many signaling cascades and cytokines have a
significant role in the recruitment of inflammatory
cells [48]. In the genital tract, the initial response of
the endometrium against infection is dependent on in-
nate immunity and mucosal defense systems [49, 50].
The uterine immune response is generated not only by
professional immune cells but also by endometrial epi-
thelial and stromal cells, which can respond to LPS
through the Toll-like receptors (TLRs) [51]. Activated
TLRs subsequently stimulate the production of pro-
inflammatory cytokines and chemokines [52].
To understand the mechanism of action of MVs, a
single concentration of 40 × 106 MVs/ml was used after
stress induced with LPS. This concentration was chosen
because, during the study of internalization, endomet-
rial cells at 24 h of culture were not saturated with
MVs and no MV degradation started.
In these experiments, we used LPS and MVs under
different conditions. In control cells, even if the apop-
tosis is higher than expected, the cell proliferation of
80 % remaining cells was very high during the 24 h of
experimentation, as proven by MTT values. Indeed,
Fig. 6 Effect of LPS and MVs under different experimental conditions on the release of TNF-α, IL-6, and TGF-β in endometrial cells. Each value
represents the mean ± SD of three samples. Values labeled with different letters are statistically different within each time point (3 h, 12 h and
24 h) (P < 0.05) CTR control, IL interleukin, LPS lipopolysaccharide, MV microvesicle, TGF transforming growth factor, TNF tumor necrosis factor
Perrini et al. Stem Cell Research & Therapy  (2016) 7:169 Page 12 of 15
viability was constantly high over the different times of
culture, and values of absorbance also did not statisti-
cally change in the presence of MVs. When the cells
were stressed with LPS, the viability decreased with re-
spect to control cells and cells cultured in the presence
of MVs. Indeed, apoptosis increased drastically after
treatment with LPS and, vice versa, the proliferation de-
clined to the same intensity. The dose of LPS (10 ng/ml)
was chosen on the basis of data obtained by Herath et
al. [53]. These authors found that this value is present in
cows with clinical endometritis. Also, over a short time,
this dose of LPS is probably also deleterious for endo-
metrial cells in a static system in vitro if compared to in
vivo environments, where this effect can be modulated.
These results underscored the stressor effect of LPS that
has been reduced by the beneficial effect of MVs on the
vitality of cells. When LPS and MVs were used at the
same time, the viability of cells was high without signifi-
cant differences compared to control cells. These results
confirm the anti-inflammatory properties of MVs. How-
ever, the beneficial effect of MVs is time-dependent. In
fact, MVs did not counteract the action of LPS if the
cells were previously exposed to LPS (3 h LPS exposure).
On the other hand, LPS does not show any detrimental
effect if the internalization of MVs in the endometrial
cells occurred 24 h before LPS treatment.
The expression of pro-inflammatory genes supports
these data. LPS induces overexpression of IL-1β at 24 h
and MVs are able to counteract this action. Indeed, at
24 h this expression is downregulated in all three experi-
mental conditions (LPS and MVs simultaneously, LPS
for 3 h and then MVs, MVs for 24 h and then LPS). This
downregulation is observed even in the experiment
where cells were previously exposed to LPS. The cells
surviving the apoptotic process are probably able to in-
corporate MVs that, at 24 h, are capable of counteract-
ing the action of LPS. The overexpression of IL-6 and
TNF-α induced by LPS occurs at 3 h and, at this time,
MVs used either simultaneously or added after the ac-
tion of LPS are not able to block the action of LPS. This
seems to indicate that the downregulation of these genes
could occur only when the cells are incubated with MVs
for a longer time to guarantee the necessary incorpor-
ation of MVs. Indeed, we found that MVs were visible
only after 6 h and increased up to 24 h.
In parallel with gene expression, the release of cyto-
kines was studied, confirming the observations regarding
gene regulation. LPS was demonstrated to be capable of
inducing the release of TNF-α the peak of which was ob-
tained 24 h after stimulation with LPS. The release of
IL-6 appeared earlier and reached the highest level 12 h
after stimulation with LPS, and then gradually decreased
over the subsequent observation period. MVs reduce the
release of these pro-inflammatory cytokines and the
maximum modulatory activity was observed between
12 h and 24 h, both when MVs were used simultan-
eously or 24 h before LPS treatment. In both cases, no
contrasting action of MVs was obtained within the first
3 h, confirming that the internalization had yet to begin.
MMP-1 and MMP-13 expression is induced by IL-1β,
so the expression of these two genes was investigated at
24 h after treatment with 10 ng/ml LPS, taking into ac-
count the higher expression of IL-1β at this time. MMP-
1 and MMP-13 expression was statistically higher com-
pared to the control, confirming the inflammatory effect
induced by LPS. Matrix metalloproteinases (MMPs) are
a family of structurally related zinc/calcium-dependent
proteinases with a pivotal role in the extracellular matrix
degradation during both normal and pathological tissue
remodeling processes [54, 55]. In addition, the MMP
collagenases are key participants in extracellular matrix
remodeling and are important for the separation of bo-
vine placental tissues from the endometrium at term
[56]. MMP-1, -2, -3, -9, and -13 are all highly expressed
in the bovine endometrium in late gestation [57], while
MMP-1 and MMP-13 expression levels are downregu-
lated in postpartum endometrium. Our study demon-
strated that MVs downregulated the expression of
MMP-1 and MMP-13 at 24 h of LPS treatment.
It is well known that miRNA-containing microvesicles
can regulate the inflammation process [58]. In this con-
text, from our results it is possible to assume that the
cargo of MVs contributed to the anti-inflammatory ef-
fect. Since MVs contain various active molecules, such
as lipids, proteins, mRNA, and miRNA [29], we studied
the presence of three miRNAs in MVs involved in the
regulation of pro-inflammatory genes in our in vitro
model (miR-335, miR-146a, and miR-26a-2). miR-335
has been demonstrated to regulate the expression of
TNF-a and IL-6 during human adipose cell inflammation
[59]. miR-146a has been demonstrated to decrease the
expression of IL-1β and, as an indirect effect, to suppress
the level of MMP in intervertebral discs in bovine spe-
cies [60]. miR-26a-2 has been widely studied and it has
been correlated with human inflammation, cell prolifera-
tion, and apoptosis [61]. The DIANA tool confirmed
that these miRNAs have predicted targets also in horse
inflammation. The downregulation of gene expression
shown in this study could be correlated to miRNA trans-
fer from MVs to endometrial cells.
Conclusion
These data provide a critical starting point for beginning
to dissect how equine amniotic MVs respond to and
alter an inflammatory situation, shown to be a promising
approach for the treatment of endometritis. Much re-
search is still needed to establish the true biological role
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of miRNAs in endometrial disease with a view to trans-
lating this knowledge into clinically effective outcomes.
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